Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.
At the 2022 American Society for Clinical Oncology Annual Meeting, durable responses continued to be shown with asciminib compared with bosutinib in adult patients with chronic myeloid leukemia in chronic phase.
Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
A 34% reduction in the risk of disease progression was observed with sacituzumab govitecan vs standard chemotherapy as treatment of patients with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.